Medical News, Journals & Upcoming Events
Latest Hematology / Oncology Articles
- Splenosis October 29, 2026A 19-year-old man with a history of splenectomy presented with chest-wall pain. Multiple enhancing soft-tissue deposits in the omentum and perirectal space were seen on CT of the abdomen and pelvis.Mariam Markouli, Jason Freed
- Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy October 25, 2026In patients with EGFR-mutated and MET-altered non–small-cell lung cancer that had progressed during osimertinib therapy, osimertinib plus savolitinib (a MET tyrosine kinase inhibitor) led to longer survival than platinum–pemetrexed.Shun Lu, Nicolas Girard, James Chih-Hsin Yang, Frances A. Shepherd, Xiaorong Dong, Surein Arulananda, Giulio Metro, Hidetoshi Hayashi, Laura Bonanno, Yu Jung Kim, Zhe Liu, Myung-Ju Ahn, Yuping Sun, Thuong Vu Le, Silvia Novello, Sang-We Kim, Yanqiu Zhao, Phuong Nguyen, Mariana Brandão, Yongsheng Wang, Missak Haigentz, Daniel Misch, Mariano Provencio Pulla, Wen-Tsung Huang, Clarissa Baldotto, Marcelo Tatangelo, Colin R. Lindsay, Ryan J. Hartmaier, Rafal Lolo, Balakumar Swaminathan, Alexander Gont, Francis Maria Esposito, Yusuke Okuma, the SAFFRON Investigators*
- Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC October 25, 2026Among patients with PD-L1–negative advanced nonsquamous non–small-cell lung cancer, progression-free survival was longer with sacituzumab tirumotecan plus pembrolizumab than with chemotherapy plus pembrolizumab (15.0 vs. 5.7 months).Fei Zhou, Xiangjiao Meng, Qingqing Ding, Peng Zhang, Wenhua Liang, Sanxing Guo, Yan Yu, Wenxiu Yao, Yun Fan, Xingxiang Pu, Chunling Liu, Jiuwei Cui, Peng Chen, Hua Zhong, Yongsheng Wang, Zhangzhou Huang, Zhi Xu, Xiaorong Dong, Tienan Yi, Ying Hu, Qiming Wang, Bolin Chen, Hui Wang, Longhua Sun, Lang He, Wei Zheng, Yina Wang, Xiaochen Zhang, Yu Yao, Yongsheng Li, Zhe Yang, Feng Ye, Xia Song, Ming Zhou, Li Yin, Yan Qing, Xiaoping Jin, Junyou Ge, Caicun Zhou
Latest Allergy & Immunology Articles
- Tozorakimab to Prevent COPD Exacerbations October 29, 2026In two replicate phase 3 trials involving patients with COPD who were receiving inhaled maintenance therapy, add-on tozorakimab resulted in a lower rate of moderate or severe exacerbations than placebo.Frank C. Sciurba, Henrik Watz, Arnaud Bourdin, Wim Janssens, Fernando J. Martinez, Jinping Zheng, Maarten van den Berge, Matteo Bonini, MeiLan K. Han, Dave Singh, Gerard J. Criner, Christopher E. Brightling, Alberto Papi, Surya P. Bhatt, Martin Jenkins, Marta Mikosz, Piotr Chołbiński, Monika Ziemiecka, Magnus Löfdahl, Deepa Arya, Madhavi Yadavalli, Bryan H. Brodek, Malin Fagerås, Samuel Bardsley, Neil Martin, Rajesh Patel, Ioannis Psallidas, the OBERON and TITANIA Trial Investigators*
- Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial October 23, 2026An interim analysis of a phase 3 randomized trial involving adults with IgA nephropathy showed that ravulizumab, a terminal complement inhibitor, led to a significantly greater reduction in proteinuria than placebo.Jonathan Barratt, Youssef M.K. Farag, Kara Rice, Tobin J. Cammett, Lesley A. Inker, Hernán Trimarchi, Annette Bruchfeld, Hiddo J.L. Heerspink, Adrian Liew, Kevin Carroll, Hong Zhang, Sayna Norouzi, Shuang Hou, Sehoon Park, Miguel Ángel Pérez Valdivia, Jai Radhakrishnan, Yusuke Suzuki, Bonnie Schneider, John Marsala, Cynthia Carrillo-Infante, Stephen L. Lake, Ajay K. Singh, Stephen Nolan, Richard A. Lafayette, the I CAN Trial Group*
- Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy October 23, 2026Among participants with IgA nephropathy, povetacicept, a dual inhibitor of B-cell activating factor and a proliferation-inducing ligand, led to a significantly greater reduction in proteinuria than placebo.Jonathan Barratt, Hong Zhang, Seung Hyeok Han, Yuzuke Suzuki, James Tumlin, Bobby Chacko, Irene L. Noronha, Arvind Madan, Raphaël Duivenvoorden, Jamil R. Azzi, Carla Nester, Cassie Dong, Neil Ahluwalia, Jiahua Li, Carmen Bozic, Ogo Egbuna, Muh Geot Wong, Richard Lafayette, the RAINIER AIS-D08 Trial Group*
To receive information about upcoming events and the latest CE Activities, join our network.
